Alnylam Pharmaceuticals
ALNY
ALNY
235 hedge funds and large institutions have $10.3B invested in Alnylam Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 68 increasing their positions, 85 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
235
Holders Change
+9
Holders Change %
+3.98%
% of All Funds
5.87%
Holding in Top 10
12
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+50%
% of All Funds
0.3%
New
45
Increased
68
Reduced
85
Closed
33
Calls
$392M
Puts
$323M
Net Calls
+$69.2M
Net Calls Change
+$60.5M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$1.01B |
| 2 |
BlackRock
New York
|
$718M |
| 3 |
O
OrbiMed
New York
|
$127M |
| 4 |
Goldman Sachs
New York
|
$211M |
| 5 |
D.E. Shaw & Co
New York
|
$115M |
Top Sellers
| 1 |
SPC
Slate Path Capital
New York
|
$65.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
$1.33B |
| 3 |
RI
RTW Investments
New York
|
$73.2M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
$12.6M |
| 5 |
BM
Bridger Management
New York
|
$45.1M |
